Genetic Variants Associated with Opioid Use Disorder
AssigneeOffice of the Ohio Attorney General
InventorJon E. Sprague
Life of this patent
Estimating the term…
Abstract
Methods and kits for diagnosing a likelihood of developing opioid use disorder (OUD) using single nucleotide polymorphisms (SNPs) are described. Also described is a method of predicting a likelihood of a subject experiencing an opioid overdose.
Claims21
A method of diagnosing a likelihood of opioid use disorder (OUD) in a patient, the method comprising:
- (a) obtaining a biological sample from the patient;
- (b) isolating DNA from the biological sample;
- (c) genotyping the DNA for one or more single nucleotide polymorphisms (SNPs), wherein the one or more SNPs include rs15524, rs776746, rs324029, rs2654754, rs2740574, or rs2069514;
- (d) determining the presence or absence of the one or more SNPs in the isolated DNA;
- and
- (e) diagnosing the patient's likelihood of developing OUD based on the presence or absence of the one or more SNPs, wherein:
- a presence of any of rs15524, rs776746, rs324029, or rs2654754 is indicative of an increased risk of developing OUD, and
- a presence of either of rs2740574 or rs2069514 is indicative of a decreased risk of developing OUD.
A diagnostic kit for diagnosing a likelihood of a subject developing opioid use disorder (OUD) based on the presence or absence of one or more single nucleotide polymorphisms (SNPs), the diagnostic kit comprising:
- (a) a set of primers or probes for genotyping two or more of rs15524, rs776746, rs324029, rs2654754, rs2740574, and rs2069514 in DNA extracted from a biological sample;
- and
- (b) instructions for using the primers or probes to diagnose the subject's likelihood of developing OUD based on the presence or absence of the SNPs.
A method of determining a subject's likelihood of developing opioid use disorder (OUD), the method comprising:
- obtaining a biological sample from the subject;
- isolating DNA from the biological sample;
- genotyping the DNA for the presence of a homozygous single nucleotide polymorphism (SNP) in the CYP3A5 gene or the DRD3 gene;
- determining whether the homozygous SNP in the CYP3A5 gene or the DRD3 gene is present in the DNA;
- and
- determining the subject is likely to develop OUD if the homozygous SNP in the CYP3A5 gene or the DRD3 gene is present in the DNA.
A method of predicting a likelihood of a subject experiencing an opioid overdose, the method comprising:
- obtaining a biological sample from the subject;
- isolating DNA from the biological sample;
- genotyping the DNA for single nucleotide polymorphisms (SNPs) comprising rs776746, rs4436578, and rs6715729;
- determining the presence or absence of the SNPs in the DNA;
- and
- diagnosing an increased risk of the subject experiencing an opioid overdose if rs776746 or rs4436578 is present in the DNA, and diagnosing a decreased risk of the subject experiencing an opioid overdose if rs6715729 is present in the DNA.
Dependencies are inferred from the claim text.